Skip to main content

Table 2 Incidence of postoperative nausea and vomiting, use of rescue emetics and complete response

From: Combination of gabapentin and ramosetron for the prevention of postoperative nausea and vomiting after gynecologic laparoscopic surgery: a prospective randomized comparative study

Parameter

Group G (n = 40)

Group R (n = 44)

Group GR (n = 40)

P overall (P 1, P 2)

Postoperative 0–2 h

 Nausea (0/1/2/3)

22*/4/10/4

22*/6/4/8

32/2/1/5

0.042

(0.017, 0.038)

 Emetic episode

4 (10.0%)

4 (9.1%)

4 (10.0%)

0.987

 Rescue antiemetics

4 (10.0%)

5 (11.4%)

5 (12.5%)

0.939

Postoperative 2–24 h

 Nausea (0/1/2/3)

21*/7/8/4

22*/12/6/4

30/3/5/2

0.041

(0.036, 0.018)

 Emetic episode

11 (27.5%)

10 (25.0%)

7 (17.5%)

0.564

 Rescue antiemetics

5 (12.5%)

6 (13.6%)

4 (10.0%)

0.874

Postoperative 24–48 h

 Nausea (0/1/2/3)

29*/8/1/2

29*/9/4/2

36/3/1/0

0.030

(0.045, 0.008)

 Emetic episode

2 (5.0%)

4 (9.1%)

1 (2.5%)

0.416

 Rescue antiemetics

2 (5.0%)

2 (4.5%)

1 (2.5%)

0.831

Postoperative 0–48 h

 Severe nausea

9 (22.5%)

11 (25.0%)

6 (15.0%)

0.510

 Emetic episode

14 (35.0%)

15 (34.1%)

9 (22.5%)

0.396

 Rescue antiemetics

10 (25.0%)

9 (20.5%)

8 (20.0%)

0.834

 Complete response

16 (40.0%)*

18 (40.9%)*

26 (65.0%)

0.038

(0.025, 0.027)

  1. Data presented as n (%) of patients
  2. Group G, patients received oral gabapentin 300 mg 1 h before induction of anesthesia; Group R, patients received intravenous ramosetron 0.3 mg at the end of surgery; Group GR, patients received oral gabapentin 300 mg 1 h before induction of anesthesia and intravenous ramosetron 0.3 mg at the end of surgery
  3. Nausea: 0, none; 1, mild; 2, moderate; 3, severe; emetic episode: retching or vomiting; complete response: absence of postoperative nausea and vomiting and no need for rescue antiemetic therapy during the 48-h postoperative period
  4. P 1 = group G vs group GR; P 2 = group R versus group GR
  5. * P < 0.05 compared with group GR